Skip to content
★ Sign in to follow
IT

ImmuneOncia Therapeutics, Inc. Stock: price and insider trades · South Korea

이뮨온시아

KR·Mcap ₩229.5BHealth Care

No insider purchase over the last 90 days. The latest, by PAIK SOONMYUNG, was filed 28 Jul 2026.

Insider Decl.
11
Thresholds
n/a
Buy Volume
€14M
10 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
유한양행7 buys
Paik Soonmyung3 buys

Since the insiders bought

  • Filed 28 May 2026 · 166 days ago · €24k
    -59.0%
    Entry ₩6,140 · Close 30 Oct 2026 ₩2,515
  • Filed 27 May 2026 · 167 days ago · €1.2M
    -62.0%
    Entry ₩6,620 · Close 30 Oct 2026 ₩2,515

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 20,198 of 26,911 companies
34.4
score / 100
Value
16
Quality
53
FCF yld-11%
Earn yld-13%
EV/EBITDA·
ROE-40%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩2,515
Analyst consensus
·
Income statement
Revenue₩111.2M
Gross profit₩111.2M100% margin
EBITDA-₩26.5B-23800% margin
Net income-₩27.4B-24605.1% margin
Balance sheet & cash
Market cap₩229.5B
Total debt₩69.5M
Free Cash Flow-₩23.2B
Debt / Equity0%
Profitability & ownership
ROE-39.7%
ROA-24.0%
% insiders56.5%
% institutions0.9%
Last declaration on 28 July 2026
Declarations11 total
  • ▲
    사외이사Executives(filed)
    €102kest.0DART
    65,240 sharesShareKRXDART:20260728000303
    Canonical exit: 26 Oct 2026 (T+90)
  • ▲
    사외이사Executives
    42M KRW15DART
    8,544 shares@ ₩4,860.000.014% mcap100.0% of flowShareKRXDART:20260528000397
    Canonical exit: 19 Aug 2026 (T+90)
  • ▲
    -Executives(filed)
    €1.2Mest.0DART
    345,503 sharesShareKRXDART:20260527000373
    Canonical exit: 25 Aug 2026 (T+90)
  • ▲
    Executives
    €1.2Mest.0DART
    346,579 sharesKRXDART:20260527000445
    Canonical exit: 20 Aug 2026 (T+90)
  • ▲
    -Executives
    4B KRW10DART
    8,669,126 shares@ ₩457.001.38% mcap100.0% of flowShareKRXDART:20260430001763
    Canonical exit: 22 Jul 2026 (T+90)
  • ▲
    Executives
    €9.2Mest.0DART
    2,271,874 sharesKRXDART:20260430001712
    Canonical exit: 22 Jul 2026 (T+90)
  • ▲
    -Executives
    0DART
    11,065,292 sharesShareKRXDART:20260422000460
    Canonical exit: 16 Jul 2026 (T+90)
  • ●
    -Executives
    0DART
    ShareKRXDART:20260323000998
  • ▲
    사외이사Executives(filed)
    €163kest.0DART
    33,000 sharesShareKRXDART:20260227008586
    Canonical exit: 28 May 2026 (T+90)
  • ▲
    대량보유자Executives
    0DART
    50,251,724 sharesKRXDART:20250523000189
    Canonical exit: 17 Aug 2025 (T+90)
  • ▲
    10%이상주주Executives(filed)
    0DART
    48,891,724 sharesShareKRXDART:20250523000201
    Canonical exit: 21 Aug 2025 (T+90)

11 of 11 declarations

About ImmuneOncia Therapeutics, Inc.

On April 23, 2026, 유한양행 bought EUR 2,285,953 at 이뮨온시아 (ImmuneOncia Therapeutics, Inc.), a South Korean health care company listed on the Korea Exchange. The other purchase with an amount is much smaller: EUR 23,752 for Paik Soonmyung (사외이사) on May 21, 2026.

The record has 11 filings, published by 2 filers between May 23, 2025 and July 28, 2026, including 10 purchases, no sale and one filing of another kind. 유한양행 filed 8, 7 of them purchases, and Paik Soonmyung 3, all purchases. From May 21, 2026 to May 27, 2026, both filers bought.

Read moreShow less

Market capitalisation is KRW 281.1 billion and insiders hold 56.5% of the capital. The record is recent: 2 filings in 2025 and 9 in 2026, all of which fall in the last twelve months, 8 of them purchases. Filings are published a median of 5 days after the trade, and there are no sales in the record.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations